Introduction
CTL-associated antigen 4 (CTLA-4, also known as CD152) has been well established as a negative regulator of T cell function (1-3). CTLA-4 ligation antagonizes early T cell activation, leading to decreased IL-2 production, inhibition of cell cycle progression, decreased induction of cyclins by anti-CD3, and modulation of TCR signaling (2, (4) (5) (6) . Mice deficient for CTLA-4 develop lymphoproliferative disease and die within 4 weeks of birth (7, 8) adding further evidence for the critical role of CTLA-4 inhibition of T cell responses. More recently, CTLA-4 has been implicated in the function of Tregs, which suppress effector T cell activation and function (9, 10) . In fact, it is clear that CTLA-4 plays a critical role in both the induction and maintenance of immune tolerance (11, 12) . Thus, many efforts have focused on developing therapeutic approaches to selectively engage this pathway to treat autoimmunity and organ transplant rejection. Unfortunately, these attempts have been largely unsuccessful due to the complex biology of CTLA-4 (13) . Early studies using Abs to target the CTLA-4 ligands B7-1 (also known as CD80) and B7-2 (also known as CD86) for immune regulation have been unreliable, as these ligands are shared with the positive costimulatory molecule CD28. Thus, rather than engaging CTLA-4 to turn off immunity, the ligands promote CD28/B7 interactions, resulting in enhanced T cell activation, expansion, and differentiation. Second, in vivo administration of anti-CTLA-4 Abs routinely acts as an antagonist of CTLA-4 function. For instance, treatment of autoimmuneprone mice with anti-CTLA-4 results in the exacerbation of diseases, including experimental autoimmune encephalomyelitis and autoimmune diabetes (14, 15) . Thus, a new approach to directly engage the CTLA-4 molecule with an agonist signal is essential for treating autoimmunity.
CTLA-4 signaling requires cross-linking in conjunction with T cell receptor engagement. This requirement is a direct consequence of the fact that CTLA-4 functions by directly influencing TCR-mediated signal transduction by altering TCR-ζ chain phosphorylation and immune synapse formation (6, 16, 17) . Thus, any effective negative signal following CTLA-4 engagement depends on the molecule being engaged, both physically and temporally, together with the TCR signal from the same APC (6) . This most likely explains why in vivo treatment of mice with anti-CTLA-4 Abs acts as an antagonist, since even Fc receptor-mediated crosslinking would not likely occur with a cell bearing the relevant antigens. We hypothesized that effective delivery of a CTLA-4 agonist would depend on presentation of a specific CTLA-4 ligand (i.e., anti-CTLA-4 Ab) on a relevant APC-bearing cognate antigen. Thus, we developed a single-chain, membrane-bound anti-CTLA-4 Ab (scFv) that can be expressed directly on APCs. In previous studies, we demonstrated that this reagent was effective in vitro in blocking T cell activation and, as predicted, was effective when presented in cis, on the same APC, during TCR signaling (18) . In this study, we have addressed the in vivo potential of such a reagent in an autoimmune setting. A construct was generated and expressed selectively on antigen-presenting B cells, which have been shown to be essential in secondary immunity and autoimmune diabetes in the NOD mouse strain (19) . The model also takes advantage of the motility of B cells that traffic to sites of antigen priming and participate in autoimmune reactions at sites of inflammation. Using this Tg mouse model, we demonstrate that cell surface-bound anti-CTLA-4 does not alter normal B or T cell development or function but selectively inhibits antigen-specific T cell function in vivo and the development of autoimmune diabetes.
Results

Generation of membrane-bound anti-CTLA-4
Tg + mice. The anti-CTLA-4 (clone 4F10) single-chain, membrane-bound (4F10scFv) construct has been well characterized in vitro and shown to have profound inhibitory effects on T cell function (18, 20) . These results prompted us to develop a Tg mouse model to test this novel construct in vivo. We chose to express the molecule on B cells since previous studies showed that the scFvmCTLA-4 was most effective when coexpressed on APCs, and B cells would be an effective cell population to selectively test antigen-specific responses. Thus, the IgM heavy-chain promoter and enhancer (PmEm) was used to drive the expression of single-chain, anti-CTLA-4 (7M−4F10scFv) (21) . In order to ensure that there would be no reverse signaling to the scFv-expressing cells, the construct was created using the transmembrane domain from B7-1, which lacked the C terminal intracytoplasmic tail (18, 20) . The PmEm 7M-4F10scFv B7-1 construct was microinjected into day 1 embryos isolated from FVB/n mice. B cell-specific 7M-4F10scFv B7-1 Tg + mice (hereafter referred to as scaCTLA-4) developed normally according to Mendelian fre-
Figure 1
Tg + scaCTLA-4 expression. Flow cytometric analysis was performed on splenocytes from scaCTLA-4 Tg + mice and littermate controls using soluble murine fusion protein mCTLA-4 Ig and anti-B220. (A) Upper panels demonstrate scaCTLA-4 on naive Tg + B cells and activated Tg + B cells following anti-IgM stimulation (48 hours, 1 mg/ml) compared with FVB littermate negative controls (lower panels). All plots were gated on B220 + B cells. (B) Flow cytometric analysis was performed on thymocytes from scaCTLA-4 Tg mice and littermate controls as described above. Flow plots illustrate scaCTLA-4 expression in DP CD4 + CD8 + thymocytes from scaCTLA-4 Tg + mice, but not DP CD4 + CD8 + thymocytes from FVB or SP CD4 + and SP CD8 + from scaCTLA-4 Tg + or FVB Tg -controls. Results shown are representative of 3 independent experiments with ≥ 3 mice per group. quencies and without gross defects. Tg scaCTLA-4 expression was identified by flow cytometry using murine CTLA-4 Ig. scaCTLA-4 expression was found on B cells isolated from the spleen and peripheral lymph nodes. Approximately 55% of the B220 + B cells isolated from spleen of Tg mice were CTLA-4 Ig positive, with a range of 30%-60% ( Figure 1A ). This staining specificity was confirmed using human CTLA-4 Ig, which did not bind (data not shown). Stimulation of B cells with anti-IgM or LPS significantly increased the expression of scaCTLA-4 Tg + to more than 80% of the B220 + B cells ( Figure 1A ). scaCTLA-4 expression was also detected on CD4 + CD8 + double-positive (DP) thymocytes but not on single-positive (SP) CD4 + or CD8 + thymocytes ( Figure 1B) , peripheral CD4 + and CD8 + T cells, macrophages, or DCs (data not shown). It is also important to note that activated CD4 + and CD8 + T cells did not express scaCTLA-4 following anti-CD3 and anti-CD28 activation (data not shown).
T and B cells develop normally in scaCTLA-4 Tg + mice. Despite scaCTLA-4 expression on DP thymocytes, T cell development appeared normal. This was evident in the thymus, with 70% CD4 + CD8 + DP, 9% CD4 + SP, and 3% CD8 + SP thymocytes for both scaCTLA-4 Tg + and littermate controls (Figure 2 ). Moreover, we did not find any changes in the peripheral T cells from lymphocytes nor significant changes in the total spleen cellularity, based on total numbers or composition. Approximately 55% B220 + B cells, 30% CD4 + T cells, and 15% CD8 + T cells were observed in both groups ( Figure 2 ). Additionally, we did not find any differences in marginal zone, follicular B cells, or transitional B cells in Tg + mice compared with controls (data not shown). CD4 + T cells constituted approximately 60% of the T cell composition of peripheral lymph nodes, with 25% being CD8 + T cells (Figure 2 ). These data indicated that although scaCTLA-4 expression was detected in the DP thymocytes, T and B cell development was normal.
scaCTLA-4 Tg + B and T cell function. The functional response of splenocytes ( Figure 3 , A and B) or purified B cells (data not shown) from scaCTLA-4 Tg + mice and littermate controls was compared using anti-IgM or LPS as mitogens. B cell proliferation, Ab production, IgM, MHC class II, CD40, B7-1, and B7-2 expression were measured. The expression of the Tg did not alter B cell responsiveness to BCR or innate stimuli ( Figure 3, A and B) . In addition, the surface expression of CD40, B7-1, B7-2, and MHC class II on naive and activated Tg + and Tg -B cells was comparable at 24, 48, and 72 hours ( Figure 3D and data not shown).
We next assessed the functional potential of the peripheral T cell compartment. Purified T cells from spleen and peripheral lymph nodes were stimulated with plate-bound anti-CD3. Peripheral T cells isolated from scaCTLA-4 Tg + mice proliferated in a dosedependent response to TCR engagement in a manner similar to control FVB T cells ( Figure 3C ). CD69 upregulation and CD62L scaCTLA-4 Tg + B cells inhibit T cell proliferation and cytokine production. Next, we examined whether the expression of scaCTLA-4 on allogeneic B cells would alter T cell activation in vitro in a mixed lymphocyte reaction (MLR). Responder C57BL/6 T cells were stimulated with MHC-mismatched purified CD19 + B cells from FVB scaCTLA-4 Tg + mice or littermate controls. T cell proliferation in response to scaCTLA-4 Tg + allogeneic MHC was significantly lower (>50% reduction, P < 0.0002 at 1:5 responder/stimulator ratio or higher) compared with control B cells ( Figure 4A ). Total splenocytes from FVB and FVB.scaCTLA-4 were not as effective (30% reduction) at inhibiting T cell priming as purified B cells (50%), suggesting endogenous DC activated the alloreactive T cells (data not shown). These data also suggest that scaCTLA-4 function did not inhibit in trans although the 30% reduction in proliferation might suggest either a trans effect or, more likely, engagement of the activated T cells with antigen-bearing non-Tg B cells or DCs. In this regard, stimulation with purified scaCTLA-4 Tg + B cells inhibited effector cytokine production in the allogeneic MLR. IFN-g production was suppressed by 83% (P < 0.006) and IL-2 production by 68% (P < 0.02) ( 
scaCTLA-4 inhibits T cell-dependent B cell Ab production in vivo.
We next determined the effects of scaCTLA-4 on immunological responses to hapten-carrier complexes in vivo. WT FVB mice received dinitrophenyl-OVA-pulsed (DNP-OVA-pulsed) B cells from either scaCTLA-4 Tg + mice or FVB controls (priming event). Seven days following initial priming, recipient mice received a boost of OVA antigen in CFA subcutaneously. DNP-specific Ab levels in sera were determined by using antigen-specific ELISA to determine levels of IgG1, IgG2a, and total Ig (days 0, 7, and 14). Mice immunized with antigen-pulsed B cells from the scaCTLA-4 Tg + mice showed significantly decreased DNP-specific Abs ( Figure 5A , P < 0.0009). There was a particular suppression of class switching to IgG2a, suggesting that coengagement of CTLA-4 during antigen exposure led to a profound suppression of Th1-dependent Ab production. We did not detect significant differences in levels of IgG1 anti-DNP Abs, indicating that scaCTLA-4 did not cause a switch to a Th2 Ab response ( Figure 5B ) consistent with the in vitro cytokine responses. Furthermore, we did not detect a significant change in total Ig levels, indicating that the effects of scaCTLA-4 were limited to antigen-specific responses ( Figure 5C ). These results demonstrate the important role CTLA-4 has in regulating T cell activity using a novel Tg approach that directly engages CTLA-4 on T cells in vivo influencing both T cell and T cell-dependent B cell responses.
Effects of CTLA-4 in 2 models of autoimmune diabetes. The scaCTLA-4 Tg + mice were crossed onto the autoimmune diabetes-prone NOD mouse model to determine the effect of scaCTLA-4 B cell expression during the development of autoimmunity. Previous studies have shown that the development of diabetes in NOD mice is critically dependent on B cells but not Ab production, suggesting that B cells are prominent APCs in this setting (22, 23) . NOD mice develop spontaneous diabetes between 12 and 30 weeks of age, with approximately 70% disease incidence in female mice in our colony. FVB.scaCTLA-4 Tg + mice were backcrossed 10 generations to the NOD background. NOD.scaCTLA-4 Tg + mice were characterized as described for the FVB.scaCTLA-4 Tg + mice for B and T cell development and function. We found similar expression of the Tg on resting and activated B cells and on DP thymocytes and no expression on resting or activated CD4 + or CD8 + peripheral T cells (data not shown). scaCTLA-4 Tg expression was not detected in cells isolated from the pancreas (data not shown). CD19 + purified scaCTLA-4 + B cells were also tested in the MLR assay as previously described and were found to inhibit allogeneic T cell responder C57BL/6 purified T cells in vitro (data not shown) similarly to the FVB.scaCTLA-4 Tg + cells (Figure 4 ). NOD.scaCTLA-4 and control NOD mice were monitored for the development of spontaneous diabetes. There was no statistical difference in insulin auto-Ab (IAA) responses in 5-, 10-, 20-, and 30-week-old NOD.scaCTLA-4 Tg + mice as compared with NOD littermates (data not shown). However, there was a significant reduction of spontaneous diabetes in NOD.scaCTLA-4 Tg + mice as compared with WT littermate NOD mice ( Figure 6 , P < 0.027). NOD diabetes incidence reached 70% (12 of 17) by 30 weeks of age while only 33% (5 of 15) of the NOD.scaCTLA-4 Tg + mice were diabetic by the end of the study period (P < 0.027). There was also a significant delay in disease kinetics and time to 25% diabetes incidence. NOD control mice were diabetic by 12.2 weeks while the same incidence frequency in the NOD.scaCTLA-4 Tg + mice did not occur until 19 weeks (P < 0.0077). Thus, expression of scaCTLA-4 Tg in NOD mice profoundly inhibited the development and progression of diabetes supporting a critical role for this pathway in autoimmunity.
Mechanism of CTLA-4-mediated inhibition: scaCTLA-4 inhibition in NOD.B7 double-knockout mice in the absence of Tregs. CTLA-4 has been proposed to be involved in Treg function (9) . CTLA-4 blockade has been shown to inhibit Treg suppression (9) and abrogate Treg-mediated protection of autoimmune colitis and transplant rejection (24, 25) . To determine if the scaCTLA-4 Tg blocks diabetes by directly inhibiting autoreactive T cells or affecting Treg activity, we took advantage of Tregdeficient NOD.B7-1.B7-2KO (NOD.B7 double-knockout [DKO]) mice. NOD.B7 DKO mice develop an accelerated form of autoimmune diabetes that begins as early as 2 weeks of age and progresses to 100 percent incidence (26) . NOD. scaCTLA-4 Tg + mice were bred with B7-deficient NOD.B7 DKO mice and monitored for diabetes development. As previously reported, diabetes was exacerbated in the NOD.B7 DKO mice with 100% incidence at 17 weeks. In contrast, ectopic expression of scaCTLA-4 suppressed the development of diabetes by 40% ( Figure 7A , P < 0.003). Consistent with this finding, the Tg + scaCTLA-4 mice that were protected from diabetes also had significantly less insulitis ( Figure 7B ). Although Tregs have been shown to be deficient in NOD.B7 DKO mice (26) , it remained possible that the engagement of CTLA-4 by the agonist scaCTLA-4 restored Tregs in the NOD.B7 DKO.scaCTLA-4 Tg + mice. We addressed this possibility by FACS analysis and determined that Tregs were not restored in NOD.B7 DKO.scaCTLA-4 Tg + mice. Both B7 DKO groups had 0.3% CD4 + CD25 hi CD62L + Tregs in comparison with 4% CD4 + CD25 hi CD62L + Tregs in WT NOD mice ( Figure 7C ). Recent studies suggest that the putative transcription factor FoxP3 is the best marker of mouse Tregs. Therefore, we repeated the analysis of B7 DKO mice, utilizing intracellular stain- 
Figure 6
NOD.scaCTLA-4 Tg + mice are protected from spontaneous diabetes. Female NOD.scaCTLA-4 Tg + mice and NOD littermate controls were monitored for the development of spontaneous autoimmune diabetes. Diabetes incidence is shown here for NOD (n = 17) (filled circles) and NOD.scaCTLA-4 Tg + (n = 15) (open circles). NOD diabetes incidence reached 70% (12 of 17) by 30 weeks of age while diabetes incidence in NOD.scaCTLA-4 Tg + mice was significantly reduced to 33% (5 of 15) by 30 weeks of age (P < 0.027).
ing of FoxP3 on CD4 + CD25 + Tregs. As seen in Figure 7D , there is a significant decrease in the percentage of CD4 + CD25 + FoxP3 + Tregs in the NOD.B7 DKO mice as compared with the NOD mice (P < 0.0002). This defect in Treg numbers was not reconstituted in NOD.B7 DKO.scaCTLA4 Tg + (P < 0.0004). Furthermore, there was no statistical difference in the number of FoxP3 + T cells between NOD.B7 DKO and NOD.B7 DKO.scaCTLA-4 Tg + mice (P < 0.95). These results suggest that the inhibition of disease by scaCTLA-4 was not due to a restoration of Tregs; rather, the scaCTLA-4 Tg may directly inhibit autoreactive T cells.
scaCTLA-4 Tg + B cells inhibit the activation of autoreactive T cells in pancreatic lymph nodes.
To further characterize T cell inhibition and test the hypothesis that CTLA-4 engagement directly inhibits autoreactive T cells, we compared islet antigen-specific T cell priming in the pancreatic LN of NOD.B7 DKO versus NOD. B7 DKO.scaCTLA-4 Tg + recipients. Islet antigen-specific TCR Tg + BDC2.5 Thy1.1 congenic CD4 + CD25 -CD62L + LN cells were labeled with CFSE and adoptively transferred into prediabetic NOD.B7 DKO or NOD.B7 DKO.scaCTLA-4 Tg + mice, and their proliferation was measured by CFSE dilution as a readout of in vivo priming (27) . Antigen-specific Tregs were depleted to address the role of scaCTLA-4 on autoreactive effector T cells in the absence of regulation (9) . As seen in Figure 8 , 70.7% (65.3% ± 4.7 %) of the autoreactive BDC2.5 cells went into cycle in the pancreatic LN from NOD.B7 DKO recipient mice compared with only 22.1% (28.8% ± 10.7 %) in NOD.B7 DKO.scaCTLA-4 Tg + recipients ( Figure 8A) . Moreover, BDC2.5 CD4 + T cells divided only 3 generations in NOD.B7 DKO.scaCTLA-4 hosts in contrast to 6 to 8 generations in the NOD.B7 DKO recipients ( Figure 8A ). There was no proliferation observed in antigen-deficient inguinal LN in either NOD.B7 DKO or NOD.B7 DKO.scaCTLA-4 Tg + mice (Figure 8A) . These results indicate that B cells bearing surface-bound anti-CTLA-4 suppress in vivo priming of autoreactive T cells in the absence of Tregs.
Next, we determined whether scaCTLA-4 similarly affects the ability of autoreactive BDC2.5 CD4 + T cells to differentiate and produce Th1 effector cytokines such as IFN-g, which is known to be involved in disease pathogenesis (28) . For this study, we utilized an IFN-g reporter mouse in which the expression of yellow fluorescent protein (YFP) is under the control of the IFN-g promoter (29) . These targeted reporter mice were designated Yeti, for yellow-enhanced transcript for IFN-g. Direct assessment of in vivo differentiation and IFN-g production can thus be measured by flow cytometry ex vivo without the requirement of in vitro restimulation. We backcrossed these mice 12 generations to NOD and subsequently bred to NOD.BDC2.5.Thy1.1 TCR Tg + 
Discussion
Although CTLA-4 engagement by B7 has been demonstrated to downregulate T cell responses in several systems, lack of appropriate reagents has prevented direct ligation in vivo to inhibit T cell function in autoimmune diseases. Rather, the majority of studies have utilized CTLA-4 antagonists or ectopic expression of B7 (which stimulate both CD28 and CTLA-4) to implicate the role of CTLA-4 in vivo (refs 14, 15 and reviewed in refs. 13, 31) . In the studies presented here, we have generated a model to examine the effect of selective engagement of CTLA-4 during in vivo immune responses. This was accomplished by expressing a single-chain, membrane-bound scFv anti-CTLA-4 selectively on B cells. Our results demonstrate that scaCTLA-4 Tg + expression did not affect T or B cell development but profoundly inhibited T cell responses to antigens presented by scaCTLA-4 Tg + B cells in vitro and in vivo. Moreover, we show that selective engagement of CTLA-4 conferred significant protection against disease in 2 models of autoimmune diabetes, even in the absence of Tregs. The mechanism for this regulation was determined to be the prevention of autoreactive T cell expansion and development of effector function.
CTLA-4 has previously been demonstrated to regulate peripheral tolerance in several experimental systems (11, 12, 32) . This regulation is at the level of T cell expansion and differentiation. In particular, we have previously shown that selective engagement of CTLA-4 using membrane-bound scaCTLA-4 inhibits antigenspecific T cell responses in vitro (18, 20) . We have also shown that scaCTLA-4 can regulate CD8 + T cell-mediated tumor clearance in an in vivo tumor model (33) . CD8 + T cells isolated from animals bearing scaCTLA-4 tumor cells were hyporesponsive ex vivo upon antigen rechallenge, indicating that CTLA-4 engagement resulted in tolerance (33) . In this study, we have extended our previous findings to show that scaCTLA-4 expression on B cells inhibits CD4 + autoimmune responses in vivo. Two separate experimental models of autoimmune diabetes were used to address the efficacy of membrane-bound anti-CTLA-4 for disease prevention. We demonstrate that selective engagement of CTLA-4 conferred significant protection against disease in spontaneous NOD diabetes and even in the more aggressive autoimmune NOD.B7-1/B7-2 KO (B7 DKO) model. This CTLA-4 control may function at several levels, including T cell activation/proliferation, Th1/Th2 differentiation, and cell trafficking. Our data suggest that scaCTLA-4-mediated inhibition is at the level of CD4 + T cell activation/differentiation. We found a significant decrease in the percentage of autoreactive BDC2.5 CD4 + T cells proliferating in the NOD.B7 DKO.scaCTLA-4 Tg + in pancreatic LN compared with controls, indicating that CTLA-4 engagement had a direct effect on antigen-specific T cell activation and expansion. CD8 + NRP-V7 + tetramer-positive cells were examined in the NOD.scaCTLA-4 Tg + mice, as these T cells have been shown to be increased during the progression of diabetes in NOD mice (34) . There were no statistical differences in the number of CD8 + NRP-V7 + antigen-specific cells in the NOD.scaCTLA-4 Tg + mice as compared with NOD mice (data not shown). We further demonstrated scaCTLA-4 significantly limited the differentiation of diabetogenic T cells toward Th1 IFN-g-producing cells. NOD.B7 DKO.scaCTLA-4 Tg + mice had significant reduction of IFN-g/YFP + cells (0.5%) compared with controls (13.3%) in islet-draining pancreatic LN. These data indicate that CTLA-4 engagement significantly inhibits both the proliferation and Th1 differentiation in an antigen-specific response. The protection from disease in this setting appears to be a result of direct inhibition of effector T cell activation/differentiation rather than regulation, as the Treg deficiency observed in NOD.B7 DKO mice was not restored by the expression of the scaCTLA-4 Tg. It is interesting to note that reduced disease incidence correlated with decreased tissue infiltration ( Figure 7B ). This is not surprising unless you consider the fact that nearly all female NOD mice develop insulitis by 3 to 4 weeks of age (35) . This lack of pancreatic infiltration indicates that CTLA-4 may function to prevent the trafficking and accumulation of inflammatory infiltrates, likely at the level of LN priming. It is important to note that the presence of the scaCTLA-4 Tg did not render these mice immunocompromised, as NOD.scaCTLA-4 Tg + mice cleared cytomegalovirus in a manner similar to that observed in NOD mice. In these experiments, NOD.RAG KO mice were used to demonstrate that immunocompromised animals were unable to clear this viral infection (data not shown). Therefore, the scaCTLA-4-mediated disease inhibition and decreased insulitis in the absence of Tregs support the interpretation that CTLA-4 ligation functioned directly on the autoreactive T cells. These data are consistent with previous findings that CTLA-4 engagement results in a tolerant state, and only after blocking CTLA-4 do tissue infiltration and autoimmunity occur.
scaCTLA-4 Tg + B cells prevent destructive insulitis and significantly affect NOD and NOD.B7 DKO mice from developing diabetes, suggesting B cells play a pivotal role in disease progression. B cells have been shown to be critical for the development of autoimmune diabetes in NOD mice, as B cell-deficient mice are protected (22, 23) . Interestingly, B cell-deficient mice develop some insulitis, suggesting that diabetogenic responses can be initiated in the absence of B cells, likely via DCs. However, diabetes fails to progress in these mice, demonstrating a critical role of B cells in the amplification of autoimmune responses and disease progression (22 scaCTLA-4 significantly delayed disease onset and development of spontaneous diabetes in NOD mice. Although there was not complete protection, there is a significant consequence of engaging CTLA-4 during development of autoimmune diabetes. There are a number of possibilities as to why B cell expression of anti-CTLA-4 was not sufficient for complete disease protection. First, autoreactive T cells may interact with several APCs during diabetes initiation. Tg B cell expression of anti-CTLA-4 may raise the threshold for T cell activation. However, it is possible that some autoreactive T cells escape scaCTLA-4 regulation and encounter islet antigens presented by DCs or macrophage cells in the absence of CTLA-4. This possibility is supported by an in vitro MLR assay where total splenocytes were used to stimulate MHC mismatched T cells. In this assay, the presence of endogenous Tg nonbearing APCs partially restored T cell proliferation. These data further support the notion that the anti-CTLA-4 is working directly on T effectors and not indirectly through Tregs. A second possibility is that CTLA-4 may function to skew the T cell repertoire. However, based on previous studies by Allison and colleagues, it would be expected that, if anything, the repertoire would be broadened to include lower affinity clones that would escape CTLA-4 inhibition due to decreased action of the inhibitory receptor (36) . A third possibility is that, over time, CTLA-4-resistant T cell clones emerge by overcoming the threshold of CTLA-4-mediated inhibition and become less dependent on costimulation. Autoimmune diabetes is a chronic progressive disease with autoreactive T cells accumulating within the target organ months prior to clinical manifestations (35) . Given the disease kinetics, it is possible that autoreactive cells may develop mechanisms to overcome or bypass CTLA-4-mediated suppression. This idea is supported by the work of You et al., where equal frequencies of diabetogenic T cells were detected in 6-week-old prediabetic and overtly diabetic NOD mice (37) . They proposed that the progression to overt disease correlates with a qualitative change in the pathogenic T cells that allows them to escape from regulation over time (37) . Thus, in a chronic progressive autoimmune disease, such as type I diabetes, evolution of pathogenic T cells is likely to post significant challenge in designing novel immunosuppressive therapies.
Overall, we have demonstrated anti-CTLA-4 Abs anchored on the surface of APCs to be an effective means to suppress autoimmune responses. There are a number of ways that can be envisioned to adapt such an approach in clinical settings to prevent graft rejection and treat autoimmunity. The first is a gene therapy approach targeting APCs, including macrophages, DCs, and B cells, to express this construct with the intent that antigen-specific responses would be selectively engaged together with CLTA-4 inhibition. A second approach shown to be effective for targeting autoimmunity was the use of a bispecific Ab to simultaneously engage antigen and CTLA-4 (38) . This approach was effective in a mouse model of thyroiditis using bispecific Abs against thyroid-stimulating hormone receptor and CTLA-4 (39). The major limitation for this strategy is the requirement of identifying and generating tissue-specific Abs against immunodominant antigens for each disease. The last approach to selectively target autoreactive and alloreactive T cells is to modify the membrane of APCs or grafted tissue with inhibitory molecules. Recent reports have demonstrated effective use of cell membrane-anchored FasL to prevent islet and cardiac graft rejection (40) . This approach utilizes a protocol to biotinylate cells and "decorate" the membrane with a chimeric protein comprised of streptavidin and FasL (40) . This is an attractive approach for the clinical setting for treatment of autoimmune disease and prevention of graft rejection. Patient cells, including B cells, macrophages, DCs and even islet grafts, could be biotinylated and modified with the addition of streptavidin scaCTLA-4. All of these therapeutic approaches are aimed toward developing a system in which antigen-specific inhibition using APCs is combined with CTLA-4-mediated inhibition.
Our results demonstrate profound inhibition of antigen-specific T and B cell responses by scaCTLA-4 Tg + B cells both in vitro and in vivo. Moreover, we show that selective engagement of CTLA-4 conferred significant protection against an exacerbated form of autoimmune diabetes. These results suggest that simultaneous engagement of CTLA-4 during antigen presentation may be an effective regimen for treating autoimmune diseases and organ graft rejections. To this end, we have focused on the generation of a construct that results in deliberate ligation of CTLA-4 in vivo and represents what we believe to be a novel immunotherapeutic approach. This type of antigen-specific approach may be useful for treating autoimmunity and inducing peripheral tolerance and warrants further development and consideration.
Methods
were pulsed with 1 mCi of 3 H-TdR (ICN Radiochemicals) during the last 8 hours of a 96-hour culture, and 3 H-TdR uptake was detected using a Packard TopCount Microplate Scintillation Counter (Packard Instruments Co.).
Statistics. Statistical significance of cytokine levels, thymidine incorporation, and mean time to 25% disease incidence was analyzed using 2-tailed Student's t test for comparisons of 2 means. Diabetes incidence statistical significance was analyzed using a nonparametric Wilcoxon signed-rank test. Values of P ≤ 0.05 were considered significant.
